TYENNE

NDC 65219-590 · Fresenius Kabi USA, LLC

Generic nameTocilizumab-aazg

Dosage formINJECTION, SOLUTION, CONCENTRATE

RouteINTRAVENOUS

Active ingredient(s)TOCILIZUMAB

Strength80 mg/4mL

Pharmacologic classInterleukin 6 Receptor Antagonists [MoA], Interleukin-6 Receptor Antagonist [EPC]

Marketing categoryBLA

Packages

65219-590-04 — 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-590-04) / 4 mL in 1 VIAL, SINGLE-DOSE

Q5135 — Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg Medicare Part B payment limit (ASP + 6%): $4.06

FDA lists these products with the same active ingredient.

50242-135 — tocilizumab, 50242-136 — tocilizumab, 50242-137 — tocilizumab, 50242-138 — tocilizumab, 50242-143 — tocilizumab, 64406-022 — Tocilizumab, 64406-023 — Tocilizumab, 64406-024 — Tocilizumab, 65219-584 — Tocilizumab-aazg, 65219-586 — Tocilizumab-aazg, 65219-592 — Tocilizumab-aazg, 65219-594 — Tocilizumab-aazg, 65219-596 — Tocilizumab-aazg, 65219-598 — Tocilizumab-aazg, 72606-042 — tocilizumab, 72606-043 — tocilizumab, 72606-044 — tocilizumab, 72606-045 — tocilizumab, 78206-200 — TOCILIZUMAB, 78206-201 — TOCILIZUMAB, +1 more

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.